



Medica Central Coverage Policy

Policy Name: Serial Dilution Endpoint Titration for Diagnosis and Treatment of Airborne Allergy MP9684

Effective Date: 01/01/2026

Important Information – Please Read Before Using This Policy

These services may or may not be covered by all Medica Central plans. Coverage is subject to requirements in applicable federal or state laws. Please refer to the member's plan document for other specific coverage information. If there is a difference between this general information and the member's plan document, the member's plan document will be used to determine coverage. With respect to Medicare, Medicaid, and other government programs, this policy will apply unless these programs require different coverage.

Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions may call the Provider Service Center. Please use the Quick Reference Guide on the Provider Communications page for the appropriate phone number. <https://mo-central.medica.com/Providers/SSM-employee-health-plan-for-IL-MO-OK-providers>

Medica Central coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment..

Coverage Policy

Serial dilution endpoint titration for airborne allergy is investigative and unproven and therefore **NOT COVERED**. There is insufficient reliable evidence in the form of high quality peer-reviewed medical literature to establish the efficacy or effects on health care outcomes.

Description

Serial dilution endpoint titration (SDET), also referred to as skin endpoint titration or intradermal dilutional testing, is a form of intradermal skin testing proposed to diagnose and treat allergy disorders. SDET involves two steps. In the first step, the antigen is administered in successive injections using increasing doses of the antigen with each injection to determine the concentration at which the reaction changes from negative to positive (the lowest dilution or "endpoint"). The second step uses the endpoint dilution as the starting dilution for immunotherapy treatment. Over the course of therapy, the antigen concentration is incrementally increased. SDET is performed in the clinical setting, and more than one allergen can be tested in this manner.

FDA Approval

SDET is a method of administering an intradermal skin test for allergy in a physician's office. Therefore, the technique is not subject to FDA approval.

Prior Authorization

Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.



Medica Central Coverage Policy

Coding Considerations

Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

CPT Codes

- **95027** - Intracutaneous (intra-dermal) tests, sequential and incremental, with allergenic extracts form airborne allergens, immediate type reaction, including test interpretation and report by a physician, specify number of tests.

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division	December 20, 2023
Revised:	Medical Policy Committee/Health Services Division	July 17, 2024
Reviewed:	Medical Policy Committee/Health Services Division	July 17, 2024

Original Effective Date: 01/01/2024

Re-Review Date(s): 08/21/2025

Administrative Update(s):

© 2026 Medica